Troriluzole

Troriluzole, a third-generation, tripeptide proagent of Riluzole (HY-B0211), is an orally active glutamate modulator. Troriluzole reduces synaptic glutamate level and increases the synaptic glutamate absorption. Troriluzole has the potential for Alzheimer disease and generalized anxiety disorder (GAD) [1][2].

Product Specifications

CAS Number

[1926203-09-9]

Product Name Alternative

BHV-4157

UNSPSC

12352005

Hazard Statement

H302, H315, H319

Target

MGluR

Type

Reference compound

Related Pathways

GPCR/G Protein; Neuronal Signaling

Applications

Neuroscience-Neurodegeneration

Field of Research

Neurological Disease; Cancer

Assay Protocol

https://www.medchemexpress.com/troriluzole.html

Concentration

10mM

Purity

99.71

Solubility

DMSO : 50 mg/mL (ultrasonic)

Smiles

O=C(CN(C)C(CNC(CN)=O)=O)NC1=NC2=CC=C(OC(F)(F)F)C=C2S1

Molecular Formula

C15H16F3N5O4S

Molecular Weight

419.38

Precautions

H302, H315, H319

References & Citations

[1]Schanzer B, et al. Novel investigational therapeutics for generalized anxiety disorder (GAD) . Expert Opin Investig Drugs. 2019 Nov;28 (11) :1003-1012.|[2]Huang LK, et al. Clinical trials of new drugs for Alzheimer disease. J Biomed Sci. 2020 Jan 6;27 (1) :18.